BMRN
BioMarin Pharmaceutical Inc.$53.31-0.49 (-0.92%)Prev Close$53.80·MCap$10.50B·P/E29.81·Vol604.1K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
8
$4.38M
◆
Net Activity
Net Seller
$4.38M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at BioMarin Pharmaceutical Inc. (BMRN) has been exclusively selling, with 0 insider purchases totaling $0.00 and 8 insider sales totaling $4.38M. The most recent insider transaction was by Guyer Charles Greg (officer: EVP, Chief Technical Officer), who sold $996.7K worth of shares on Mar 12, 2026. BioMarin Pharmaceutical Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $10.50B.
BMRN Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | Guyer Charles Greg | officer: EVP, Chief Technical Officer | Sell | 16,486 | $60.46 | $996.7K | 79,953 |
| Feb 26, 2026 | Davis George Eric | officer: EVP, Chief Legal Officer | Sell | 26,061 | $61.36 | $1.60M | 72,453-26% |
| Feb 26, 2026 | Friberg Gregory R | officer: EVP, Chief R&D Officer | Sell | 6,326 | $60.38 | $381.9K | 37,578 |
| Dec 1, 2025 | Hardy Alexander | Chief Executive Officer | Sell | 16,570 | $55.03 | $911.8K | 0 |
| Sep 30, 2025 | Friberg Gregory R | EVP, Chief R&D Officer | Sell | 3,304 | $54.16 | $178.9K | 0 |
| May 20, 2025 | Hubbard Cristin | EVP, Chief Commercial Officer | Sell | 2,155 | $59.93 | $129.1K | 0 |
| May 19, 2025 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 2,782 | $59.30 | $165.0K | 0 |
| May 2, 2025 | Hubbard Cristin | EVP, Chief Commercial Officer | Sell | 273 | $64.92 | $17.7K | 0 |
| Mar 19, 2025 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 1,295 | $71.52 | $92.6K | 0 |
| Mar 14, 2025 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 823 | $69.44 | $57.1K | 0 |
| Mar 14, 2025 | Davis George Eric | EVP, Chief Legal Officer | Sell | 16,249 | $69.44 | $1.13M | 0 |
| Mar 14, 2025 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 20,127 | $69.44 | $1.40M | 0 |
| Mar 14, 2025 | Hardy Alexander | Chief Executive Officer | Sell | 2,933 | $69.44 | $203.7K | 0 |
| Mar 14, 2025 | Mueller Brian | EVP, Chief Financial Officer | Sell | 18,497 | $69.44 | $1.28M | 0 |
| Mar 6, 2025 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 7,034 | $71.28 | $501.4K | 0 |
| Feb 28, 2025 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 4,287 | $71.16 | $305.1K | 0 |
| Feb 24, 2025 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 1,344 | $68.38 | $91.9K | 0 |
| Nov 29, 2024 | Hardy Alexander | Chief Executive Officer | Sell | 14,295 | $66.03 | $943.9K | 0 |
| Nov 12, 2024 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 5,278 | $66.37 | $350.3K | 0 |
| Sep 13, 2024 | FUCHS HENRY J | President, Worldwide R&D | Sell | 12,098 | $84.90 | $1.03M | 0 |
| Aug 13, 2024 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 714 | $90.00 | $64.3K | 0 |
| Jun 28, 2024 | Mueller Brian | EVP, Chief Financial Officer | Sell | 588 | $82.33 | $48.4K | 0 |
| Jun 3, 2024 | HERON ELAINE J | Director | Sell | 4,168 | $76.41 | $318.5K | 0 |
| Jun 3, 2024 | MEIER RICHARD A | Director | Sell | 5,451 | $76.41 | $416.5K | 0 |
| May 30, 2024 | Mueller Brian | EVP, Chief Financial Officer | Sell | 5,000 | $75.19 | $375.9K | 0 |
| May 28, 2024 | Davis George Eric | EVP, Chief Legal Officer | Sell | 40,850 | $74.51 | $3.04M | 0 |
| May 20, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 1,202 | $77.05 | $92.6K | 0 |
| May 17, 2024 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 993 | $76.97 | $76.4K | 0 |
| May 9, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 40,000 | $81.38 | $3.26M | 0 |
| May 3, 2024 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 4,440 | $82.44 | $366.0K | 0 |
| May 2, 2024 | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Sell | 5,000 | $82.91 | $414.6K | 0 |
| May 2, 2024 | Davis George Eric | EVP, Chief Legal Officer | Sell | 1,850 | $85.01 | $157.3K | 0 |
| Apr 11, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 40,000 | $91.13 | $3.65M | 0 |
| Apr 10, 2024 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 2,286 | $90.00 | $205.7K | 0 |
| Mar 28, 2024 | Davis George Eric | EVP, Chief Legal Officer | Sell | 24,602 | $88.34 | $2.17M | 0 |
| Mar 18, 2024 | Slamon Dennis | Director | Sell | 9,510 | $83.81 | $797.0K | 0 |
| Mar 15, 2024 | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Sell | 22,580 | $83.87 | $1.89M | 0 |
| Mar 15, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 85,209 | $83.87 | $7.15M | 0 |
| Mar 15, 2024 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 372 | $83.87 | $31.2K | 0 |
| Mar 15, 2024 | Davis George Eric | EVP, Chief Legal Officer | Sell | 21,699 | $83.87 | $1.82M | 0 |
| Mar 15, 2024 | FUCHS HENRY J | President, Worldwide R&D | Sell | 33,485 | $83.87 | $2.81M | 0 |
| Mar 15, 2024 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 20,424 | $83.87 | $1.71M | 0 |
| Mar 15, 2024 | Mueller Brian | EVP, Chief Financial Officer | Sell | 20,789 | $83.87 | $1.74M | 0 |
| Mar 5, 2024 | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Sell | 4,000 | $87.07 | $348.3K | 0 |
| Mar 5, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 2,000 | $86.11 | $172.2K | 0 |
| Mar 5, 2024 | FUCHS HENRY J | President, Worldwide R&D | Sell | 35,341 | $85.18 | $3.01M | 0 |
| Feb 27, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 1,000 | $90.35 | $90.3K | 0 |
| Jan 18, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 30,040 | $89.03 | $2.67M | 0 |
| Jan 8, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 20,050 | $97.29 | $1.95M | 0 |
| Dec 21, 2023 | BIENAIME JEAN JACQUES | Director | Sell | 10,000 | $93.99 | $939.9K | 0 |
Showing 1–50 of 155
1 / 4
BMRN Insider Buying Activity
The following table shows recent insider purchases of BioMarin Pharmaceutical Inc. (BMRN) stock reported via SEC Form 4 filings.
No insider buying activity found for BMRN in the last 12 months.
BMRN Insider Selling Activity
The following table shows recent insider sales of BioMarin Pharmaceutical Inc. (BMRN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | Guyer Charles Greg | officer: EVP, Chief Technical Officer | Sell | 16,486 | $60.46 | $996.7K | 79,953 |
| Feb 26, 2026 | Davis George Eric | officer: EVP, Chief Legal Officer | Sell | 26,061 | $61.36 | $1.60M | 72,453-26% |
| Feb 26, 2026 | Friberg Gregory R | officer: EVP, Chief R&D Officer | Sell | 6,326 | $60.38 | $381.9K | 37,578 |
| Dec 1, 2025 | Hardy Alexander | Chief Executive Officer | Sell | 16,570 | $55.03 | $911.8K | 0 |
| Sep 30, 2025 | Friberg Gregory R | EVP, Chief R&D Officer | Sell | 3,304 | $54.16 | $178.9K | 0 |
| May 20, 2025 | Hubbard Cristin | EVP, Chief Commercial Officer | Sell | 2,155 | $59.93 | $129.1K | 0 |
| May 19, 2025 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 2,782 | $59.30 | $165.0K | 0 |
| May 2, 2025 | Hubbard Cristin | EVP, Chief Commercial Officer | Sell | 273 | $64.92 | $17.7K | 0 |
| Mar 19, 2025 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 1,295 | $71.52 | $92.6K | 0 |
| Mar 14, 2025 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 823 | $69.44 | $57.1K | 0 |
| Mar 14, 2025 | Davis George Eric | EVP, Chief Legal Officer | Sell | 16,249 | $69.44 | $1.13M | 0 |
| Mar 14, 2025 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 20,127 | $69.44 | $1.40M | 0 |
| Mar 14, 2025 | Hardy Alexander | Chief Executive Officer | Sell | 2,933 | $69.44 | $203.7K | 0 |
| Mar 14, 2025 | Mueller Brian | EVP, Chief Financial Officer | Sell | 18,497 | $69.44 | $1.28M | 0 |
| Mar 6, 2025 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 7,034 | $71.28 | $501.4K | 0 |
| Feb 28, 2025 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 4,287 | $71.16 | $305.1K | 0 |
| Feb 24, 2025 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 1,344 | $68.38 | $91.9K | 0 |
| Nov 29, 2024 | Hardy Alexander | Chief Executive Officer | Sell | 14,295 | $66.03 | $943.9K | 0 |
| Nov 12, 2024 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 5,278 | $66.37 | $350.3K | 0 |
| Sep 13, 2024 | FUCHS HENRY J | President, Worldwide R&D | Sell | 12,098 | $84.90 | $1.03M | 0 |
| Aug 13, 2024 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 714 | $90.00 | $64.3K | 0 |
| Jun 28, 2024 | Mueller Brian | EVP, Chief Financial Officer | Sell | 588 | $82.33 | $48.4K | 0 |
| Jun 3, 2024 | HERON ELAINE J | Director | Sell | 4,168 | $76.41 | $318.5K | 0 |
| Jun 3, 2024 | MEIER RICHARD A | Director | Sell | 5,451 | $76.41 | $416.5K | 0 |
| May 30, 2024 | Mueller Brian | EVP, Chief Financial Officer | Sell | 5,000 | $75.19 | $375.9K | 0 |
| May 28, 2024 | Davis George Eric | EVP, Chief Legal Officer | Sell | 40,850 | $74.51 | $3.04M | 0 |
| May 20, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 1,202 | $77.05 | $92.6K | 0 |
| May 17, 2024 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 993 | $76.97 | $76.4K | 0 |
| May 9, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 40,000 | $81.38 | $3.26M | 0 |
| May 3, 2024 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 4,440 | $82.44 | $366.0K | 0 |
| May 2, 2024 | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Sell | 5,000 | $82.91 | $414.6K | 0 |
| May 2, 2024 | Davis George Eric | EVP, Chief Legal Officer | Sell | 1,850 | $85.01 | $157.3K | 0 |
| Apr 11, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 40,000 | $91.13 | $3.65M | 0 |
| Apr 10, 2024 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 2,286 | $90.00 | $205.7K | 0 |
| Mar 28, 2024 | Davis George Eric | EVP, Chief Legal Officer | Sell | 24,602 | $88.34 | $2.17M | 0 |
| Mar 18, 2024 | Slamon Dennis | Director | Sell | 9,510 | $83.81 | $797.0K | 0 |
| Mar 15, 2024 | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Sell | 22,580 | $83.87 | $1.89M | 0 |
| Mar 15, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 85,209 | $83.87 | $7.15M | 0 |
| Mar 15, 2024 | Burkhart Erin | GVP, Chief Accounting Officer | Sell | 372 | $83.87 | $31.2K | 0 |
| Mar 15, 2024 | Davis George Eric | EVP, Chief Legal Officer | Sell | 21,699 | $83.87 | $1.82M | 0 |
| Mar 15, 2024 | FUCHS HENRY J | President, Worldwide R&D | Sell | 33,485 | $83.87 | $2.81M | 0 |
| Mar 15, 2024 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell | 20,424 | $83.87 | $1.71M | 0 |
| Mar 15, 2024 | Mueller Brian | EVP, Chief Financial Officer | Sell | 20,789 | $83.87 | $1.74M | 0 |
| Mar 5, 2024 | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | Sell | 4,000 | $87.07 | $348.3K | 0 |
| Mar 5, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 2,000 | $86.11 | $172.2K | 0 |
| Mar 5, 2024 | FUCHS HENRY J | President, Worldwide R&D | Sell | 35,341 | $85.18 | $3.01M | 0 |
| Feb 27, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 1,000 | $90.35 | $90.3K | 0 |
| Jan 18, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 30,040 | $89.03 | $2.67M | 0 |
| Jan 8, 2024 | BIENAIME JEAN JACQUES | Director | Sell | 20,050 | $97.29 | $1.95M | 0 |
| Dec 21, 2023 | BIENAIME JEAN JACQUES | Director | Sell | 10,000 | $93.99 | $939.9K | 0 |
BMRN Insiders
Similar Stocks to BMRN
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B